Apremilast for the treatment of generalized granuloma annulare: A case series of 8 patients
Abstract
To the Editor:We read with interest the case series by Blum and Altman exploring the role of apremilast in the treatment of generalized granuloma annulare (GA). GA is a challenging entity to treat, and despite its significant psychosocial impact, there exists a paucity of treatment options for this condition. Here, we present a case series of 8 patients with generalized GA treated with apremilast. Eight patients with generalized GA (6 women and 2 men) ranging in age from 52 to 80 years (median, 64 years) were treated with apremilast 30 mg twice daily. A variable response to apremilast treatment was observed (Table I). Three patients experienced complete clearance of GA: patient 2 had complete lesion clearance at 6 months, with durable remission at 2-year follow-up; patient 4 had 90% lesion clearance at 6 months, at which point she discontinued apremilast and has sustained remission at 1 year; and patient 7 also experienced a complete response to treatment at 6 months with sustained response at 1 year. However, 3 patients failed apremilast—patient 1 had decreased lesion erythema at 3 months, but the erythema returned at 6 months of treatment; patient 3 had no response at 6 months; and patient 6 had decreased lesion erythema at 5 months, but there was no change in lesion size. Patient 8 had complete clearance of
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 8 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.